SHINE Medical Technologies of Janesville makes it’s first commercial sales of an isotope used to treat cancer.
Director of Marketing and Corporate Communications Rod Hise says lutetium-177 is a low-energy beta-particle emitter that works by directly irradiating cancer cells after being delivered to the cancer site by a targeting molecule. Lu-177 is used to treat neuroendocrine cancers. It also shows promise for the treatment of metastatic prostate and other cancers.
Hise says SHINE’s recent sales of Lu-177 are a significant milestone for the company and important validation of our production and commercial processes.
